Enovis (NYSE:ENOV) Stock Price Down 5.6% – Here’s What Happened

Enovis Corporation (NYSE:ENOV) was down 5.6% during mid-day trading on Thursday . The stock traded as low as $25.26 and last traded at $24.9690. Approximately 373,186 shares changed hands during mid-day trading, a decline of 64% from the average daily volume of 1,039,166 shares. The stock had previously closed at $26.46.

Wall Street Analyst Weigh In

Several analysts have recently issued reports on ENOV shares. Wells Fargo & Company dropped their target price on shares of Enovis from $42.00 to $40.00 and set an “overweight” rating on the stock in a research report on Friday, May 8th. Evercore reiterated an “outperform” rating and issued a $36.00 target price on shares of Enovis in a research report on Friday, May 8th. Needham & Company LLC lifted their target price on shares of Enovis from $49.00 to $52.00 and gave the company a “buy” rating in a research report on Thursday, February 26th. Zacks Research raised shares of Enovis from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, March 4th. Finally, Wall Street Zen raised shares of Enovis from a “hold” rating to a “buy” rating in a research note on Sunday, May 10th. One investment analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $44.50.

Enovis Stock Down 1.8%

The company has a debt-to-equity ratio of 0.87, a current ratio of 2.04 and a quick ratio of 1.05. The business’s 50 day simple moving average is $24.01 and its 200 day simple moving average is $25.32. The company has a market capitalization of $1.39 billion, a PE ratio of -1.22 and a beta of 1.41.

Enovis (NYSE:ENOV) last issued its earnings results on Thursday, May 7th. The company reported $0.89 EPS for the quarter, topping analysts’ consensus estimates of $0.82 by $0.07. Enovis had a negative net margin of 49.92% and a positive return on equity of 10.32%. The company had revenue of $589.15 million for the quarter, compared to the consensus estimate of $572.02 million. During the same period in the previous year, the firm earned $0.81 earnings per share. Enovis’s quarterly revenue was up 5.4% compared to the same quarter last year. Enovis has set its FY 2026 guidance at 3.520-3.730 EPS. As a group, analysts anticipate that Enovis Corporation will post 3.65 earnings per share for the current fiscal year.

Insider Activity

In related news, insider Oliver Engert purchased 1,000 shares of Enovis stock in a transaction dated Friday, February 27th. The shares were acquired at an average cost of $25.50 per share, with a total value of $25,500.00. Following the purchase, the insider owned 43,640 shares of the company’s stock, valued at approximately $1,112,820. The trade was a 2.35% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Over the last quarter, insiders have purchased 5,000 shares of company stock valued at $121,983. 2.90% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Enovis

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Arax Advisory Partners acquired a new position in shares of Enovis in the fourth quarter valued at approximately $29,000. EverSource Wealth Advisors LLC grew its holdings in shares of Enovis by 125.4% in the second quarter. EverSource Wealth Advisors LLC now owns 1,271 shares of the company’s stock valued at $40,000 after purchasing an additional 707 shares in the last quarter. GAMMA Investing LLC grew its holdings in shares of Enovis by 353.5% in the fourth quarter. GAMMA Investing LLC now owns 1,855 shares of the company’s stock valued at $49,000 after purchasing an additional 1,446 shares in the last quarter. Atlantic Union Bankshares Corp acquired a new position in shares of Enovis in the third quarter valued at approximately $64,000. Finally, Danske Bank A S acquired a new position in shares of Enovis in the third quarter valued at approximately $64,000. 98.45% of the stock is owned by hedge funds and other institutional investors.

About Enovis

Enovis is a global medical technology company focused on advancing the field of musculoskeletal health. Formed through the separation of the MedTech business from Colfax Corporation in 2021, Enovis brings together a portfolio of specialized products and services designed to address conditions affecting the foot and ankle, hand and wrist, sports medicine, joint repair, biologics and rehabilitation.

The company’s flagship offerings include minimally invasive implants and instrumentation for foot and ankle surgery under the Treace Medical Concepts brand, focal joint resurfacing implants through Arthrosurface, and synthetic bone graft substitutes marketed as NovaBone.